GALECTIN THERAPEUTICS INC - COM NEW (GALT) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / COM NEW
Symbol
GALT on Nasdaq
Price per share
$4.16
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
10,315,270
Total reported value
$43,896,766
% of total 13F portfolios
0%
Share change
-197,146
Value change
-$59,971
Number of holders
84
Price from insider filings
$4.16
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

As of 30 Sep 2025, 84 institutional investors reported holding 10,315,270 shares of GALECTIN THERAPEUTICS INC - COM NEW (GALT).

Institutional Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 170,234 $683,170 +$9,997 $4.16 8
2025 Q3 10,315,270 $43,896,766 -$59,971 $4.24 84
2025 Q2 10,463,242 $22,085,893 +$1,798,912 $2.11 84
2025 Q1 9,907,188 $12,120,102 -$167,181 $1.22 88
2024 Q4 10,110,015 $13,012,103 -$70,473 $1.29 94
2024 Q3 9,746,940 $26,802,293 +$625,575 $2.75 78
2024 Q2 9,417,077 $21,280,501 +$4,010,257 $2.26 71
2024 Q1 7,591,787 $18,144,362 +$1,149,883 $2.39 57
2023 Q4 7,221,573 $11,998,463 -$3,154,063 $1.66 66
2023 Q3 9,051,475 $17,375,764 +$3,461,982 $1.92 59
2023 Q2 7,271,442 $10,470,025 +$114,381 $1.44 58
2023 Q1 7,155,735 $15,019,803 +$222,174 $2.10 55
2022 Q4 7,105,475 $8,031,212 +$165,111 $1.13 58
2022 Q3 6,925,544 $11,283,983 -$167,283 $1.63 51
2022 Q2 7,046,893 $9,228,368 -$579,530 $1.31 53
2022 Q1 7,459,376 $12,001,681 -$281,390 $1.61 53
2021 Q4 7,325,883 $15,165,161 -$499,136 $2.07 52
2021 Q3 7,287,350 $28,239,646 -$2,237,797 $3.88 66
2021 Q2 7,893,506 $25,251,481 -$5,902,902 $3.20 70
2021 Q1 9,406,177 $20,414,792 -$1,888,720 $2.17 68
2020 Q4 10,768,536 $23,988,956 +$1,272,225 $2.24 74
2020 Q3 10,045,218 $26,830,365 -$333,937 $2.67 67
2020 Q2 10,161,248 $31,077,126 +$1,533,958 $3.06 73
2020 Q1 9,676,162 $18,961,521 -$1,077,308 $1.96 72
2019 Q4 10,063,446 $28,783,662 +$1,845,277 $2.86 75
2019 Q3 9,386,211 $34,438,974 +$3,018,308 $3.67 75
2019 Q2 8,481,799 $35,182,714 +$4,361,160 $4.15 71
2019 Q1 7,300,056 $37,300,204 +$9,156,802 $5.11 62
2018 Q4 5,731,512 $19,686,137 -$2,548,068 $3.43 57
2018 Q3 6,014,860 $36,148,300 +$2,413,240 $6.01 58
2018 Q2 5,574,695 $35,452,254 +$4,184,678 $6.36 66
2018 Q1 4,979,115 $23,594,190 +$6,247,048 $4.74 57
2017 Q4 3,732,462 $12,473,134 -$430,534 $3.34 45
2017 Q3 3,888,235 $8,295,086 -$6,442 $2.13 45
2017 Q2 3,831,156 $9,418,000 +$860,773 $2.46 44
2017 Q1 3,625,185 $8,336,000 +$2,110,920 $2.30 39
2016 Q4 2,848,806 $2,787,000 -$227,562 $0.98 35
2016 Q3 3,032,931 $3,425,775 -$602,452 $1.13 41
2016 Q2 3,500,347 $5,142,675 -$566,403 $1.47 44
2016 Q1 3,488,141 $4,983,000 -$242,724 $1.43 41
2015 Q4 3,586,091 $5,871,000 +$1,284,078 $1.64 49
2015 Q3 2,652,972 $7,015,000 -$1,738,505 $2.34 41
2015 Q2 3,325,529 $9,074,596 -$2,104,345 $2.73 52
2015 Q1 4,048,478 $13,570,527 +$950,442 $3.35 56
2014 Q4 3,758,562 $13,036,775 -$3,098,185 $3.47 58
2014 Q3 4,279,131 $21,526,740 -$4,779,569 $5.03 60
2014 Q2 4,244,719 $58,616,737 +$8,957,096 $13.81 61
2014 Q1 3,468,577 $53,101,000 +$31,889,795 $15.31 49